COVID-19 Resources
Resources are updated on an ongoing basis. Last updated September 4, 2025.
Press Releases
2025
5/31 – Moderna Receives U.S. FDA Approval for COVID-19 Vaccine mNEXSPIKE
5/23 – Moderna Files FDA Application for the LP.8.1 Targeting COVID-19 Vaccine
1/24 – Moderna Awarded Tender for the Supply of Its mRNA COVID-19 Vaccine in the European Union
2024
12/20 – Moderna – The Hidden Cost of COVID – Long COVID's Impact on the Workforce
8/29 – Moderna Launches National Awareness Campaign to Help Drive COVID-19 Vaccination
8/22 – Celebrating U.S. FDA Approval of Our Updated COVID-19 Vaccine
8/15 – COVID-19 Summer Surge – Three Things to Know
7/31 – Understanding Long COVID’s Impact on the Workforce
6/7 – Moderna Files FDA Application for the JN.1 Targeting COVID-19 Vaccine
2023
9/11 – Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccine
9/6 – 3 Things to Know About the 2023-2024 COVID-19 Season
6/29 – MODERNA INITIATES ROLLING SUBMISSION TO HEALTH CANADA FOR UPDATED COVID-19 VACCINE
6/22 – Moderna Files for FDA Authorization of Its Updated COVID-19 Vaccine
5/24 – Leveraging 13 Years of Investment in mRNA Innovation for Future Pandemic Preparedness
2022
11/4 – Moderna Receives Health Canada Authorization for Second Omicron-Targeting Bivalent Booster
9/11 – Indonesia's Bio Farma ready to produce 'IndoVac' Covid-19 vaccines
9/1 – Health Canada Authorizes Moderna's Omicron-Targeting Bivalent COVID-19 Booster Vaccine
7/14 – Health Canada Authorizes Moderna's COVID-19 Vaccine in Young Children (6 Months-5 Years)
6/2 – Moderna and the European Commission Agree on Amendment to COVID-19 Vaccine Supply Agreement
4/19 – Moderna Announces Clinical Update on Bivalent COVID-19 Booster Platform
3/17 – Health Canada Authorizes Moderna's COVID-19 Vaccine in Children (6-11 Years)
2021
12/20 – Moderna Announces Preliminary Booster Data and Updates Strategy to Address Omicron Variant
12/13 – Moderna and Australia Announce Collaboration to Bring mRNA Manufacturing to Australia
11/26 – Moderna Announces Strategy to Address Omicron (B.1.1.529) SARS-CoV-2 Variant
10/26 – Moderna Announces Swissmedic Authorizes Booster Dose of Moderna's COVID-19 Vaccine
9/24 – Moderna Announces Supply Agreement with Peru for 20 Million Doses of Its COVID-19 Vaccine
9/16 – Moderna Announces Health Canada Approves its COVID-19 Vaccine
9/15 – Moderna Highlights New Clinical Data on its COVID-19 Vaccine
9/08 – Resilience to Manufacture mRNA for Moderna's COVID-19 Vaccine
9/01 – Moderna Announces Submission of Initial Data to U.S. FDA for Its COVID-19 Vaccine Booster
6/16 – U.S. Government Purchases Additional 200 Million Doses of Moderna's COVID-19 Vaccine
6/07 – Moderna Files for Authorization with Health Canada for its COVID-19 Vaccine in Adolescents
6/03 – Moderna Announces Agreement to Supply the Republic of Botswana with its COVID-19 Vaccine
5/22 – Moderna and South Korea Explore Collaboration on mRNA Vaccines
5/21 – Ministry of Food and Drug Safety of South Korea (MFDS) Authorizes Moderna's COVID-19 Vaccine
5/21 – Japan's Ministry of Health, Labour and Welfare (MHLW) Approves Moderna's COVID-19 Vaccine
5/05 – Moderna Announces Positive Initial Booster Data Against SARS-CoV-2 Variants of Concern
4/20 – Moderna Announces New Supply Agreement with Israel for 2022
2/17 – European Commission Purchases Additional 150 Million Doses of COVID-19 Vaccine Moderna
2/16 – Moderna Provides U.S. COVID-19 Vaccine Supply Update
2/12 – Canada Purchases Additional 4 Million Doses of Moderna's COVID-19 Vaccine
2/11 – U.S. Government Purchases Additional 100 Million Doses of Moderna's COVID-19 Vaccine
1/25 – Moderna to Host Conference Call on COVID-19 Variants Announcement on Monday, Jan. 25
1/12 – Swissmedic Authorizes COVID-19 Vaccine Moderna for Use in Switzerland
1/06 – European Commission Authorizes COVID-19 Vaccine Moderna in Europe
1/04 – Moderna Provides COVID-19 Vaccine Supply Update
1/04 – Israeli Ministry of Health Authorizes COVID-19 Vaccine Moderna for Use in Israel
2020
12/23 – Health Canada Authorizes Moderna COVID-19 Vaccine in Canada
12/18 – Moderna Announces FDA Authorization of Moderna COVID-19 Vaccine in U.S.
11/13 – Swissmedic Begins Rolling Review of Moderna's mRNA Vaccine Against COVID-19 (mRNA-1273)
9/8 – Biopharma Leaders Unite To Stand With Science
7/27 – Moderna Announces Phase 3 COVE Study of mRNA Vaccine Against COVID-19 (mRNA-1273) Begins
6/11 – Moderna Advances Late-Stage Development of its Vaccine (mRNA-1273) Against COVID-19
2/24 – Moderna Ships mRNA Vaccine Against Novel Coronavirus (mRNA-1273) for Phase 1 Study